¡Ya estamos en ! Descubre más
118.28 USD
-3.01
2.48%
Al cierre Actualizado 16 oct, 4:00 p.m. EDT
Antes de la apertura del mercado
Después del cierre del mercado
118.52
+0.24
0.2%
1 día
-2.48%
5 días
-0.35%
1 mes
11.33%
3 meses
50.68%
6 meses
96.77%
En lo que va del año
47.89%
1 año
137.65%
5 años
76.35%
10 años
243.14%
 

Acerca de: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

Empleados: 3,009

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 59.3%
Neutral 29.6%
Negativo 11.1%
Positivo
Zacks Investment Research
hace 18 horas
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
Negativo
Zacks Investment Research
ayer
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Positivo
Zacks Investment Research
hace 3 días
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Positivo
Zacks Investment Research
hace 7 días
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Positivo
Proactive Investors
hace 8 días
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
Haemonetics (NYSE:HAE) shares jumped over 13% to $115.20 on Thursday after CSL set out a timetable for moving its US plasma collection centers onto the company's devices. CSL Limited (ASX:CSL), the Australian biotechnology company, expects to finish rolling out Haemonetics' NexSys PCS devices with Persona PLUS technology and related disposables by the end of 2027.
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
Positivo
Barrons
hace 8 días
Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
CSL Plasma plans to use Haemonetics' plasma collection equipment across all existing U.S. centers, expanding the scope of an earlier supply agreement.
Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
Positivo
Zacks Investment Research
hace 11 días
PAHC vs. HAE: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
PAHC vs. HAE: Which Stock Is the Better Value Option?
Neutral
PRNewsWire
hace 16 días
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026.
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
Positivo
Zacks Investment Research
hace 22 días
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
Positivo
Zacks Investment Research
hace 28 días
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
Gráficos de precios implementados con Lightweight Charts™